LNSR Company Profile and Key Details

LNSR has shown mixed momentum, gaining 3.99% over the past week and 1.27% over the past quarter, though year-to-date performance is up 3.18%. Short-term trend indicators are mixed aligned (SMA20 -2.08%, SMA50 -1.13%, SMA200 -3.17%). The stock’s 14-day RSI is 47.34 (neutral), while the ATR of 0.4 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.48% below its high and over 29.19% above its low. Average 10-day trading volume of 280.65 thousand shares is significantly above the 3-month average of 68.61 thousand, indicating heightened recent market interest.

LENSAR, Inc. generated EPS of -$4.39 over the past year. Five-year average earnings growth is -14.63%. The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.07. Next year's EPS is expected at $54.00. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $10.00. The high target offers 117.71% upside. The low target suggests 45.14% downside. The mean target is $12.50. This offers 81.42% upside. LENSAR, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 287.5%. The prior quarter beat by 87.5%. Over the last six quarters, Apple has recorded several small beats. These include 172.41% in August 08, 2024.

LENSAR, Inc. has 11.93 million shares outstanding. The public float is 8.64 million shares, elevated short interest at 5.97% of float. This equals 515.99 thousand shares. The short ratio is 7.55 days. Institutional investors hold 59.38% of the float. Insiders own 19.41%. PDL BIOPHARMA, INC. holds 8.67 million shares, STAAB THOMAS R II has 135.13 thousand shares and Winer Gary M has 80.84 thousand shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

LENSAR, Inc. (NASDAQ:LNSR) closed at $6.58 USD, losing -$0.31 (-4.50%) from the previous close of $6.89. The stock is currently trading near its 52-week low $6.55 and $17.31. With a market capitalization of about $78.60 million, LENSAR, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.73). Key stats such as the average daily volume over the past year has been around 69.13 thousand shares, trading with heavier-than-usual volume. Headquartered in Orlando, FL, LENSAR, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Nicholas T. Curtis, the company employs approximately 140 people and listed since October 02, 2020. LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.

LENSAR, Inc. trades at a P/E ratio of -1.54, slightly below the S&P 500 average, with a price-to-sales ratio of 1.33 and a price-to-book ratio of -6.54 indicating negative book value, which may reflect financial stress. The P/FCF stands at -6.62, also below market averages.

Our AI price prediction model suggests that LENSAR, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.24%, with price expected at $7.94 by March 31, 2026, within a range of $7.34 to $8.63 3-Month Outlook: Projected fall of -69.67%, reaching $2.09 by June 15, 2026, with a range of $1.74 to $2.43. 1-Year Outlook: Projected gain of 175.33%, with price at $18.97 by March 17, 2027, within a range of $18.79 to $19.13.

LENSAR, Inc. (NASDAQ:LNSR) shares are flat 3.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows LENSAR, Inc. trading at a premium to the broader market with a P/E of -1.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.25, suggesting 121.34% upside. Our AI forecast model points to short-term strength (15.24% over two weeks), a medium-term fall (-69.67% over three months), and a longer-term gain (175.33% over one year), with expected trading ranges indicating moderate volatility.